European Commission Approves Vertex’s Next-Generation Cystic Fibrosis Therapy, ALYFTREK®
Vertex Pharmaceuticals has announced that the European Commission has approved its newest cystic fibrosis treatment, ALYFTREK a once-daily, triple-combination therapy made up of deutivacaftor, tezacaftor, and vanzacaftor.






















